Document:

EXHIBIT 4.7

 

INVESTMENT AGREEMENT

 

THIS INVESTMENT AGREEMENT (this
"Agreement") is made and entered into as of February 17, 2017 (“Effective Date”) by and among:

 

投资人一:中关村转化医学科技有限公司
(以下简称“ZTMST”或投资人一), 依据中华人民共和国法律成立的公司, 统一社会信用代码:911101083355172390, 

 

注册地址:中华人民共和国北京市海淀区永丰屯538号1号楼101

 

the Investor1: Zhongguancun Translational
Medicine Science & Technology Co., Ltd. (hereinafter referred to as “ZTMST” or the Investor1), a company registered
under the laws of People's Republic of China, Company registration number 911101083355172390, having its principal place of business
located at Room 101, Building 1, 538 Yongfengtun, Haidian District, Beijing, China 

 

投资人二:重庆两江源创转化医学科技有限公司
(以下简称“CLYTMST”或投资人二), 依据中华人民共和国法律成立的公司, 统一社会信用代码:91500000MA5U8WD90, 

 

注册地址:中华人民共和国重庆市两江新区水土工业园区云禾路62/64/66号

 

the Investor2: Chongqing
Liangjiang Yuanchuang Translational Medicine Science & Technology Co., Ltd. (hereinafter referred to as
“CLYTMST” or the Investor2 ), a company registered under the laws of People's Republic of China, Company
registration number 91500000MA5U8WD90, having its principal place of business located at No. 62/64/66 Yunhe Road, Shuitu
Industrial Park, Liangjiang New District, Chongqing, the P.R.China

 

投资人三:北京巴斯巴生物医学工程科技发展有限公司(以下简称“BASIBA
”或投资人三), 依据中华人民共和国法律成立的公司, 统一社会信用代码:91110108MA004HDLXC

 

     

     

    

  

注册地址:中华人民共和国北京市海淀区永丰屯538号1号楼258室

 

the
Investor3: Beijing BASIBA Biomedical Engineering Science & Technology Development Co., Ltd. (hereinafter referred to
as “BASIBA” or the Investor3), a company registered under the laws of People's Republic of China, Company registration
number 91110108MA004HDLXC,
having its principal place of business located at No. 258, Building 1, No. 538 Yongfeng, Haidian District, Beijing, the P.R. China

 

投资人四:北京济士大泽生物科技中心(以下简称“Jishi”或投资人四), 依据中华人民共和国法律成立的公司, 统一社会信用代码:91110108MA0091RL20, 

 

注册地址:中华人民共和国北京市海淀区永丰屯538号1号楼337室

 

the
Investor4:Beijing Jishi Daze Biological Science & Technology Center (hereinafter referred to as “Jishi”
or the Investor4), a company registered under the laws of People's Republic of China, Company registration number 91110108MA0091RL20,
having its principal place of business located at No. 337, Building 1, No. 538 Yongfeng, Haidian District, Beijing, the P.R. China

 

投资人一、投资人二、投资人三和投资人四(统称为“投资人”)为本协议项下的投资、以及任何未来投资人在公司或为公司采取的作为或不作为行动的一致行动人, 其中, 投资人一为牵头方。

 

the Investor1, the Investor2, the Investor3
and the Investor4 (collectively referred to as the “Investor”) are concerned parties in the investment
under this Agreement and any future act or omission of the Investor in or for the Company, among which the Investor1 is the leading
party .

 

and

 

Nano Textile Ltd., a company registered
under the laws of Israel, Company registration number 514997741, having its principal place of business located at 14 Sade Itzhak,
Nahariya 2230507, and Israel (hereinafter referred to as the “Company”

 

     

     

    

  

[“Parties” shall mean
Investor and the Company or either of them when used in the singular form].

 

WHEREAS, The Board of Directors
of the Company (the "Board") has determined that it is in the best interests of the Company to raise capital
by means of issuance of up to 35,256,844of the Company’s shares (the “Shares”) to the Investor, on the
terms and conditions more fully set forth in this Agreement on a fully diluted basis;

 

and

 

WHEREAS, under the Memory of Understanding
(the “MOU”) by and between the Company and ZTMST, as the leading party of the Investor, dated December 19,
2016, the Investor transferred to the Company an advance payment in the amount of US$ 200,000 on (the “Down Payment”),
to grant 3% of the issued and outstanding equity securities of the Company; and

 

WHEREAS, the Investor wishes to
further invest in the Company pursuant to the terms and conditions more fully set forth in this Agreement.

 

NOW, THEREFORE, in consideration
of the mutual promises and covenants set forth herein, the Parties hereby agree as follows:

 

		1.	Preamble Schedules and Interpretation

 

		1.1.	The preamble and Schedules hereto
                                         constitute an integral part hereof.

 

		1.2.	The headings of the sections and
                                         subsections of this Agreement are for reference only, and are not to be considered in
                                         construing this Agreement.

 

		1.3.	For the purpose of this Agreement
                                         and to clarify the territory for future sub-license territory, “China” means
                                         the People’s Republic of China including the Hong Kong Special Administrative Region,
                                         the Macao Special Administrative Region but not the Taiwan Region.

 

		1.4.	The Company Technology shall mean:
                                         Using roll to roll machine for single action process both at once:  Breakdown of
                                         metal oxides to Nano scale particles and Embedment onto fabric’s surface to make
                                         become antibacterial.

 

		2.	Issue and Sale of Shares.

 

		2.1.	Subject
                                         to the terms and conditions hereof, at the Closing (as defined below) the Company shall
                                         issue and allot to the Investor, in consideration of a total of Two Million US Dollars
                                         (US$2,000,000) (the "Investment Amount") 35,256,844 shares (the "Shares"),
                                         or other number of shares that on the Closing shall be equal to 30% of the issued and
                                         outstanding equity securities of the Company (the “Investment”) on
                                         a fully diluted basis, among which:

 

     

     

    

  

		2.1.1	The Company shall
                                         issue in favor of the Investor1 35% of the new issued and outstanding equity securities
                                         of the Company, i.e. 12,339,896 shares, representing 10.5% of the all issued and outstanding
                                         equity securities of the Company (including the 3% that were granted to Investor 1 in
                                         consideration for the advance payment).

 

		2.1.2	The Company shall
                                         issue in favor of the Investor2 35% of the new issued and outstanding equity securities
                                         of the Company, i.e.12,339,896 shares , representing 10.5% of the all issued and outstanding
                                         equity securities of the Company.

 

		2.1.3	The Company shall
                                         issue in favor of the Investor3 15% of the new issued and outstanding equity securities
                                         of the Company, i.e. 5,288,526 shares, representing 4.5% of the all issued and outstanding
                                         equity securities of the Company.

 

		2.1.4	The Company shall
                                         issue in favor of the Investor4 15% of the new issued and outstanding equity securities
                                         of the Company, i.e. 5,288,526 shares, representing 4.5% of the all issued and outstanding
                                         equity securities of the Company.

 

		2.2.	The investment
                                         from the Investor will be used for the following: industrial manufacture including but
                                         not limited to: factory rent, purchase machines and related equipment and staff, scale
                                         up, optimization etc, promoting technological development of additional applications
                                         of the technology, product promotion and marketing and penetrating markets worldwide.
                                         Development of additional applications etc. day to dayy management and staff salaries,
                                         prompting the trade in the OTC market, developing the patents and extend the patent and
                                         their protection, raising further funds, as described in the budget and business plan
                                         Schedule 1 as attached.

 

		3.	Plans for transitional
                                         period of the investment

 

		3.1	Transitional
                                         period of the investment is a period from the execution date of this Agreement to the
                                         completion of changing registration for shareholding with competent authority.

 

     

     

    

  

		3.2	During the Transitional
                                         period the Company shall carry on the business in the ordinary and proper course and
                                         in strict accordance with Israeli laws and regulations; and the Company shall inform
                                         the Investor regarding any substantial or material change in the Company’s policy
                                         and\or operation and\or business and\or financials and\or any other actions that will
                                         bring significant adverse impact on the Company;

 

		4.	Closing of Issue 

 

		4.1.	The
                                         Closing. Subject to the terms and conditions of this Agreement, the issuance
                                         and allotment by the Company to the Investor of the Shares shall take place until April
                                         30 2017 or until any Extended Closing Date according to the parties’ written agreement.
                                         The Closing shall be held remotely via the exchange of documents and signatures or such
                                         other time as the Company and the Investor mutually agreed upon in writing (the “Closing”).

 

		4.2.	Transactions
                                         at the Closing. At the Closing, the following transactions shall occur, which
                                         transactions shall be deemed to take place simultaneously and no transaction shall be
                                         deemed to have been completed or any document delivered until all such transactions have
                                         been completed and all required documents delivered:

 

		4.2.1.	The Investor shall deliver the
                                         following items to the Company:

 

		(a)	The Investment Amount: 2 million
                                         USD (US$2,00,000) (hereinafter: the “Closing Amount”) shall be transferred
                                         to the Company's Bank Account upon the Closing Date, and in no event later than April
                                         30, 2017 or an extended date as shall be agreed by the Parties..(the "Closing"
                                         or "Closing Date" or “Extended Closing Date”).

 

		(b)	The Investor shall provide the
                                         Company with a formal bank document approving the transfer of the Closing Amount.

 

		(c)	Investor alone shall be responsible
                                         to obtain prior to the Effective Date and/or Closing Date any documents and/or approval
                                         required by law, including any third party written waivers and/or approvals which may
                                         be required for the execution of this Agreement, including without limitation, any approval
                                         or recordation by government authorities on the transaction, such as MOFCOM, SAFE, tax
                                         and other authorities concerned, if required. The Investor shall deliver a copy to the
                                         Company of any such documents and approvals obtained. In any event, any delay in the
                                         obtainment of any of the above shall not justify any delay in the transfer of the Closing
                                         Amount, and shall not delay such transfer.

 

		(d)	In the event that the Closing Amount
                                         is not transferred to the Company as of the Closing Date, as applicable, in full by the
                                         Closing Date, but Investor 2 transferred the consideration of 700,000 USD to the Company
                                         then, for an amicable cooperation, the Company shall consider to extend the Closing
                                         Date for a period of 30 days until May 31, 2017 for the Investor to have additional time
                                         for the approval and recordation process. During the Extended Closing Term, the Investor
                                         and the Company shall jointly make efforts to settle the payment issue (including but
                                         not limited to the full payment to be made by any one or more of the four Investors,
                                         or any third party to be confirmed by the Investor and the Company).

 

     

     

    

  

		(e)	only in case the Investor still
                                         cannot pay in full before May 31, 2017, the Company shall be be entitled to one of the
                                         following: (1) change the agreement that the Company will not issue the shares equal
                                         to 30% of the issued and outstanding equity securities of the Company but issue 35,256,844__________________shares
                                         . (2) Impose the Investor the liquidated damages in the ratio of 0.25% per week (odd
                                         days shall be deemed as a full week) from June1, 2017 until the Extended Closing Date
                                         as shall be agreed by the parties. (3) To annul this Agreement by written notification
                                         to the Investor, and the Investor shall not be entitled to any compensation or right
                                         except for the shares granted under the MOU. The above shall not derogate from any other
                                         remedy to which Company shall be entitled to.

 

		4.2.2.	The Company shall deliver to the
                                         Investor the following documents:

 

		(a)	A true and correct copy of the
                                         resolutions of the Company's shareholders in the form attached hereto as Schedule
                                         2 approving (i) the Company’s execution, delivery and performance of this
                                         Agreement, and any other ancillary documents to which the Company is a party hereby and
                                         thereby; (ii) the issuance of the Shares to the Investor against payment of the Investment
                                         Amount in accordance with the terms of this Agreement; (iii) in case the AOA shall be
                                         amended, the adoption of the Amended and Restated Articles of Association of the Company
                                         and/or Shareholders agreement (the “Amended Articles”);

 

		(b)	A true and correct copy of a resolution
                                         of the Company's Board of Directors (the "Board") in the form attached
                                         hereto as Schedule 3 approving, inter alia, (i) the Company’s execution,
                                         delivery and performance of this Agreement, and any other ancillary documents to which
                                         the Company is a party hereby and thereby; (ii) the issuance of the Shares to the Investor
                                         against payment of the Investment Amount in accordance with the terms of this Agreement;

 

		(c)	the Company shall provide a true
                                         and correct copy of the Company’s share register, in which the issuance of the
                                         Shares has been registered in the name of the Investor and a copy of a notice which shall
                                         be filed with the Israeli Registrar of Companies about the share issuance and a copy
                                         of a notice which shall be filed with the Israeli Registrar of Companies about the appointment
                                         of the Investor’s director in the forms attached hereto as Schedule 4;

 

On the Closing
Date, and as a condition to the Closing, the Investor shall deliver the full Investment Amount to the Company in immediately available
funds.

 

     

     

    

  

		5.	Management of the Company

 

		5.1.	This
                                         Agreement and the contemplated issuance of the Shares according thereto shall not affect
                                         the operations of the Company's business which shall remain in the hands of the Company's
                                         current management team subject to the approval of the annual budget by the Board.

 

		5.2.	After
                                         the Closing the Investor shall be entitled to be represented on the Board according to
                                         their equivalent shareholding percentage in the Company.

 

		6.	Representations and Warranties
                                         of the Parties

 

		6.1.	Organization.
                                         The Company is duly organized and validly existing under the laws of Israel. The Company
                                         has been listed in OTCBB with 12,255,732 registered shares out of the total 81,995,969
                                         issued shares of the Company.

 

		6.2.	Authorization.
                                         Each Party represents that it has the full power and authority to execute and deliver
                                         this Agreement and to consummate the transactions contemplated hereby, and the execution
                                         and delivery of this Agreement have been authorized by all necessary corporate action.
                                         There is no legal or other impediment preventing either Party from entering into this
                                         Agreement.

 

		6.3.	Any
                                         Company shares issued according to this Agreement will be duly and validly issued, fully
                                         paid and non-assessable and will be free and clear of all liens, charges, restrictions,
                                         claims and encumbrances imposed by or through the Company, conferring onto their holder
                                         such rights, preferences and privileges as set forth in the Company's Amended Articles.

 

		6.4.	Financial
                                         Statements. Attached as Schedule 5 are the Company's audited consolidated
                                         financial statements as of and for the year ending December 31, 2015, and the Company’s
                                         unaudited balance sheet/management report for 2016.

 

		6.5.	Business
                                         Plan and Budget. The Company’s business plan and budget for the year 2017,
                                         in the form attached hereto as Schedule 1 (the "Budget"), has
                                         been prepared in good faith and with professional care by the Company. To the Company's
                                         best knowledge, there are no other material facts or matters of which the Company is
                                         aware of, which may render the Budget untrue or misleading in any material way.

 

		6.6.	Other
                                         than as explicitly stipulated herein, no representations and warranties of any kind are
                                         given with respect to the Shares and/or with respect to the Company.

 

		6.7.	The
                                         Investor declares and warrants that it knows the Company and its business, and that it
                                         has made all the examinations it deems necessary in connection with this Agreement and
                                         the issuance and transfer of the Shares contemplated herein, and further declares and
                                         agrees that it and/or anyone on its behalf shall have no claims, demands, suits and/or
                                         contentions in connection thereto.

 

     

     

    

  

		6.8.	Authority;
                                         No Breach. The consummation of the transactions contemplated hereunder and the performance
                                         of this Agreement by the Investor do not violate any applicable law, and will not result
                                         in any breach of, or constitute a default under, any agreement or instrument to which
                                         he is a party or under which it is bound. The execution and performance of this Agreement
                                         by the Investor have been duly authorized by all necessary actions (if applicable), and
                                         this Agreement has been duly executed and delivered by the Investor. This Agreement is
                                         valid and binding upon it and enforceable in accordance with its terms.

 

		6.9.	Disclosure
                                         of Information. The Investor has had an opportunity to ask questions of the management
                                         of the Company and to obtain all information necessary to permit an informed evaluation
                                         of the benefits and risks associated with the transactions contemplated hereunder (including,
                                         without limitation, financial, legal, patent, technology and know-how, strategic, and
                                         other aspects of the transactions contemplated hereby). The Investor acknowledges and
                                         agrees that other than as set forth in this Agreement, the Company makes no representation
                                         or warranties to the Investor, with respect to the Shares and/or with respect to the
                                         Company.

 

		6.10.	Experience.
                                         The Investor has experience in investing in securities of companies in the development
                                         stage and acknowledges that it is able to fend for itself, can bear the economic risk
                                         of a total loss of his investment, and has such knowledge and experience in financial
                                         or business matters that it is capable of evaluating the merits and risks of the investment
                                         in the Shares pursuant to this Agreement.

 

		6.11.	The
                                         Investor undertakes that, as long as it holds any shares in the Company (a) all of the
                                         activities of the Investor and any affiliate thereof which is related to the Company's
                                         business or that may compete with the Company's business shall be performed by it and
                                         by all such affiliates solely and exclusively within the frame and for the benefit of
                                         the Company; (b) it will not, directly or indirectly: (i) be engaged in any activities,
                                         including without limitations development activities, relating to the Company's business;
                                         or (ii) carry on or hold control (50% or more of the voting power) and/or serve in any
                                         significant position, such as a director or an office holder in any company, venture,
                                         entity or other business (other than a minority interest in a publicly traded company)
                                         which directly competes with the products or services of the Company.

 

In addition
to the above representations and warranties, for the accomplishment of expected purpose under this Agreement, the Company makes
the following specific representations and warranties to the Investor on the execution date of this Agreement, and confirm that
Investor’s entering into this Agreement is based on the full reliance of following representations and warranties:

 

(1)

 

Any agreements, contracts and legal documents
to which the Company as one party, are lawful and effective and are binding on related parties. the Company and its related parties
have appropriately performed their obligations under these agreements, contracts and legal documents according to the laws and
contracts, and there is no breach behaviors that will lead to significant adverse impact on these contracts and circumstances
that will cause any such breach; all important contracts that has been signed but not performed by the Company have already been
disclosed to the Investor;

 

     

     

    

  

(2)

 

Other than the stock option plan and other
due diligence documents disclosed by the Company, there is no other plan and arrangements on share motivation, stock option, remuneration
related to profit and profit sharing bonus between the Company and shareholders, employees, consultants and any other subjects;

 

Other than the debts disclosed by the
Company, as of the execution date of this Agreement, the Company has no any other debts or contingent debts to external parties.

 

(4)

 

Other than what has been disclosed, there
are no affiliated transactions between existing shareholders or affiliated parties of the existing shareholders and the Company;

 

(5);

 

Other than what has been disclosed, as
of the execution date of this Agreement, the Company does not involve, participate in any litigation or arbitrations;

 

(6);

 

As of the execution date of this Agreement,
there is no guarantee made by the Company in favor of external parties;

 

(7)

 

Patents, no matter they are self-owned
or licensed, are stable.

 

(8)

 

The Company undertakes that any information
provided for the due diligence for this investment, and any representation and warranty that it makes herein is true, accurate
and not misleading.

 

		7.	Use of Proceeds. The
                                         proceeds of the Investment Amount shall be used by the Company as in accordance with
                                         the Budget as attached in Schedule 1.

 

     

     

    

  

		8.	Confidentiality. The
                                         Investor shall keep in strict confidence any and all information pertaining to the Company’s
                                         business and shall not make any unauthorized disclosure of any proprietary information
                                         of the Company concerning activities of the Company and technology regarding the Company’s
                                         product research and development, patents, copyrights, customers, trade secrets and test
                                         results, processes, data and know-how, improvements, inventions, techniques and products
                                         (actual or planned), confidential information or knowledge (including, but not limited
                                         to the processes and technologies utilized and to be utilized in the Company's business,
                                         the methods and result of the Company's research, technical or financial information,
                                         or any other information or data relating to the business of the Company or any information
                                         with respect to any of the Company's customers and/or intellectual property), whether
                                         oral or in writing or in any other form, obtained by the Investor with respect to the
                                         Company. The aforesaid covenants regarding confidentiality shall be binding upon the
                                         Investor indefinitely and shall survive termination of the relationship between the Parties,
                                         for any reason.

 

		9.	Taxes

 

Each Party
will bear its own taxes and expenditures related to the negotiation of this Agreement and its execution.

 

		10.	Governing Law and Jurisdiction

 

		10.1.	This
                                         Agreement shall be governed by and construed in accordance with and governed by the laws
                                         (but not the conflict of laws rules) of the State of Israel, and the sole and exclusive
                                         jurisdiction and venue of any controversy or claim arising out of this Agreement shall
                                         be finally settled under the Rules of Arbitration of the Israeli Institute for Commercial
                                         Arbitration founded by the Federation of Israeli Chambers of Commerce.

 

		11.	Other relevant agreement on
                                         the investment

 

		11.1.	The
                                         Company offers to the Chinese JV to be implemented between the Company and the Investor
                                         in China an exclusive sublicense to use its Technology for the Chinese market only in
                                         China, all according and subject to the license agreement as shall be signed between
                                         the parties and subject to the Company’s agreement with Bar Ilan university. Also,
                                         the Company agrees to coordinate its existing investors and/or patent holders and/or
                                         other licenses/distributors to consider to take the future JV between the Company and
                                         the Investor to be established in China as a global production base.

 

		11.2.	Aside
                                         from the direct investment of US$2,000,000.00 in the Company, the Investor is planning
                                         to invest US$ 1,000,000.00 in a JV between the Company and the Investor (without cash
                                         to be invested from the Company), which allows strategic collaboration and transfer of
                                         technology. The investors’ shareholding in the JV is 70% and the Company’s
                                         shareholding in the JV is 30% all according and subject to the JV agreement as shall
                                         be signed between the parties and subject to the Company’s agreement with Bar Ilan
                                         University

 

     

     

    

  

		12.	Board Composition and Resolution
                                         .

 

		12.1.	Upon
                                         Closing, and according to the current shareholders ratio in the company the Board of
                                         Directors of the Company shall be composed of 6 directors, of whom, 4 are appointed by
                                         the existing shareholders and 2 are appointed by and Investors.

 

		12.2.	Any
                                         resolution regarding the usage of the Investment that will be substantially out of the
                                         scope of the usage of the investment as described in 2.2 in the agreement and Schedule
                                         1, shall be unanimously approved by all directors in a duly singed Board Resolution.

 

		12.3.	For
                                         as long as the Investor holds at least ten (10%) of the issued and outstanding share
                                         capital of the Company, it shall have the right to appoint, remove and replace one (1)
                                         non-voting observer to the Board (an “Observer”),
                                         who shall receive all notices of the Board meetings and shall receive any and all documentations
                                         provided to the members of the Board of Directors, subject to the provisions hereof.
                                         Such Observer shall be entitled to all information and notification rights afforded to
                                         members of the Board, provided that such Observer shall agree to hold in confidence and
                                         trust and to act in a fiduciary manner with respect to all information so provided and
                                         undertake to disclose any potential conflicts of interest and to remove itself from Board
                                         meetings and not be furnished with documents and materials in the event of a conflict
                                         reasonably foreseeable or ascertainable by the Observer. It is hereby clarified that
                                         the identity of the Observer is subject to the Company’s approval.

 

     

     

    

  

		12.4.	The
                                         Board may exclude Observer from participating in a meeting or any portion thereof, or
                                         from receiving information, documents or material afforded to members of the Board, in
                                         circumstances were such Observer, had he/she been a member of the Board, would have been
                                         excluded from such meeting. For the avoidance of doubt, the Observer’s
                                         right to attend the meetings of the Board shall not apply to resolutions in writing made
                                         by the Board, and shall not prevent the members of the Board from making such written
                                         resolutions (provided that the Observer shall receive copies of all such written resolutions).

 

		13.	Miscellaneous

 

		13.1.	Entire
                                         Agreement; Amendment and Waiver. This Agreement and the Schedules attached hereto
                                         constitute the entire agreement between the Parties with regard to the subject matters
                                         hereof. Any term of this Agreement may be amended and the observance of any term hereof
                                         may be waived (either prospectively or retroactively and either generally or in a particular
                                         instance) only with an agreement in writing duly signed by the Parties. . In the event
                                         of any conflict between this Agreement (or any portion thereof) and any other agreement
                                         between the parties, the terms of this Agreement shall prevail.

 

		13.2.	Further
                                         Assurances. Each of the Parties hereto shall perform such further acts and execute
                                         such further documents as may reasonably be necessary to carry out and give full effect
                                         to the provisions of this Agreement and the intentions of the Parties. Attached hereto
                                         as Schedule 6 is a list of the documents a certified copy of which, the
                                         Investor, shall provide to the Company promptly following the Closing for the purpose
                                         of providing required reports to state authorities and/or financial institutions.

 

     

     

    

  

		13.3.	Successors
                                         and Assigns; Assignment. Except as expressly limited herein, the provisions hereof
                                         shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors,
                                         and administrators of the Parties. None of the rights, privileges, or obligations set
                                         forth in, arising under, or created by this Agreement may be assigned or transferred
                                         without the prior written consent of each Party to this Agreement.

 

		13.4.	Notices.

 

		13.4.1	All notices required hereunder
                                         to be given to a Party shall be in writing and shall be telecopied or mailed by registered
                                         or certified mail, postage prepaid, or otherwise delivered by hand or by messenger, addressed
                                         to such Party's address as set forth above in the preamble to this Agreement or such
                                         other address with respect to a party as such party shall notify each other party in
                                         writing.

 

		13.4.2	Any notice sent in accordance with
                                         this Agreement shall be effective (i) if mailed, five (5) business days after mailing,
                                         (ii) if sent by messenger, upon delivery, and (iii) if sent via telecopier, upon transmission
                                         and electronic confirmation of receipt or (if transmitted and received on a non-business
                                         day) on the first business day following transmission and electronic confirmation of
                                         receipt.

 

		13.5.	Severability.
                                         If any provision of this Agreement is held by a court of competent jurisdiction to be
                                         unenforceable, then such provision shall be excluded from this Agreement and the remainder
                                         of this Agreement shall be interpreted as if such provision were so excluded and shall
                                         be enforceable in accordance with its terms; provided, however, that in such event this
                                         Agreement shall be interpreted so as to give effect, to the greatest extent permitted
                                         by applicable law, to the meaning of the excluded provision.

 

		13.6.	Counterparts.
                                         This Agreement may be executed in any number of counterparts, each of which shall be
                                         deemed an original and enforceable against the Parties actually executing such counterpart,
                                         and all of which together shall constitute one and the same instrument.

 

     

     

    

  

IN WITNESS WHEREOF, the Parties
hereto have caused this Agreement to be executed as of the day and year first above written.

 

	 	Investor:	 
	 	 	 
	 	/s/	 
	 	中关村转化医学科技有限公司

         

        Zhongguancun Translational Medicine Science &
        Technology Ltd.
	 

 

	 	By:	 	 
	 	Title:	 	 
	 	Date:	2017.2.17	 

 

     

     

    

  

	IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the day and year first above written.
	 	 	 
	 	Investor:	 
	 	 	 
	 	/s/	 
	 	重庆两江源创转化医学科技有限公司	 
	 	 	 
	 	Chongqing Liangjiang Yuanchuang Translational
    Medicine Science & Technology Co., Ltd.	 

 

	 	By:	 	 
	 	Title:	 	 
	 	Date:	2017.2.17	 

 

     

     

    

  

	IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the day and year first above written.
	 	 	 
	 	Investor:	 
	 	 	 
	 	/s/	 
	 	北京巴斯巴生物医学工程科技发展有限公司	 

 

	 	Beijing BASIBA Biomedical Engineering
    Science & Technology Development Co., Ltd.	 
	 	 	 
	 	By: 	 	 
	 	Title: 	 	 
	 	Date:  	2017.2.17	

 

     

     

    

  

	IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the day and year first above written.
	 	 	 
	 	Investor:	 
	 	 	 
	 	/s/	 
	 	北京济士大泽生物科技中心	 
	 	 	 
	 	Beijing Jishi Daze Biological Science &
    Technology Center	 

 

	 	By: 	 	 
	 	Title: 	 	 
	 	Date:  	2017.2.17	 

 

     

     

    

  

	IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the day and year first above written.
	 	 	 
	 	The Company	 
	 	 	 
	 	/s/ Joshua
    Herchcovici	 
	 	 	 
	 	Nano Textile Co.	 

 

	 	By: 	Joshua Herchcovici	 
	 	Title: 	Chairman	 
	 	Date: 	17.2.2017EXHIBIT 4.8

 

AMENDMENT TO INVESTMENT AGREEMENT

(the “Amendment”)

 

THIS AMENDMENT
is made and entered into as of February 17, 2017,

 

BY AND AMONG

 

Investor1: Zhongguancun Translational
Medicine Science & Technology Co., Ltd. (hereinafter referred to as “ZTMST” or "Investor 1") , a
company registered under the laws of People's Republic of China, Company registration number 911101083355172390, having its principal
place of business located at Room 101, Building 1, 538 Yongfengtun, Haidian District, Beijing, China;

 

Investor 2: Chongqing Liangjiang
Yuanchuang Translational Medicine Science & Technology Co., Ltd. (hereinafter referred to as “CLYTMST” or "Investor
2"), a company registered under the laws of People's Republic of China, Company registration number 91500000MA5U8WD90, having
its principal place of business located at No. 62/64/66 Yunhe Road, Shuitu Industrial Park, Liangjiang New District, Chongqing,
the P.R.China;

 

Investor 3: Beijing BASIBA Biomedical
Engineering Science & Technology Development Co., Ltd. (hereinafter referred to as “BASIBA” or "Investor
3"), a company registered under the laws of People's Republic of China, Company registration number 91110108MA004HDLXC, having
its principal place of business located at No. 258, Building 1, No. 538 Yongfeng, Haidian District, Beijing, the P.R. China;

 

Investor 4: Beijing Jishi
Daze Biological Science & Technology Center (hereinafter referred to as “Jishi” or "Investor 4"),
a company registered under the laws of People's Republic of China, Company registration number 91110108MA0091RL20, having its principal
place of business located at No. 337, Building 1, No. 538 Yongfeng, Haidian District, Beijing, the P.R. China; (Investor 1, Investor
2, Investor 3, and Investor 4 (collectively referred to as the “Investor”)are concerned parties in the
investment under this Amendment);

 

AND

 

The Company: Nano-Textile
Ltd., a company registered under the laws of Israel, Company registration number 514997741, having its principal place of business
located at 14 Sade Itzhak, Nahariya 2230507 Israel (hereinafter referred to as the “Company”).

 

WHEREAS, the
Investor and the Company entered into an Investment Agreement dated February 17, 2017, (the “Agreement”), pursuant
to which the Investor agreed to invest Two Million U.S. Dollars (US$2,000,000) in the Company; and

 

WHEREAS, the
parties wish to amend certain provisions of the Agreement as detailed herein, while otherwise leaving the terms and conditions
of the Agreement in full force and effect;

 

NOW THEREFORE
the parties, through their authorized representatives, hereby agree to amend the Agreement as follows:

 

     

     

    

 

1.          Except
as specifically modified by this Amendment, the terms and conditions of the Agreement shall remain in full force and effect. In
the event of any inconsistency between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment
shall control. All capitalized terms used herein shall have the meaning ascribed to them in the Agreement, unless defined otherwise
herein.

 

2.          The
parenthetical clause at the end of Section 2.1.1 of the Agreement shall be revised to read as follows: "(including the 3%
that was referenced in Section 2(c) of the non-binding MOU)."

 

3.          Section
4.2.1(e)(3) of the Agreement shall be revised to read as follows: "(3) To annul this Agreement by written notification to
the Investor, and the Investor and the Company shall not be entitled to any compensation or right except for the issuance of shares
in consideration for the Down Payment made by the Investor pursuant to the non-binding MOU."

 

4.          Section
4.2.2(a) of the Agreement shall be deleted in its entirety. There is no requirement for shareholder approval under applicable law.

 

5.          Section
5.2 of the Agreement shall be amended to read as follows:

 

"5.2           The
Investor and Joshua Herchcovici, the majority shareholder of the Company, shall enter into a voting agreement whereby Mr. Herchcovici
will undertake to vote his shares in the Company after the Closing in a manner so as to elect
to the Board of Directors of the Company such number of directors designated in writing by the Investor such that the percentage
of members of the Board of Directors designated by the Investor shall be equal to the Investor's shareholding percentage in the
Company."

 

6.          Section
6.1 of the Agreement shall be amended to read as follows:

 

"6.1           The
Company has been quoted on the OTC Pink, with 12,255,732 registered shares out of the total 82,265,969 issued shares of the Company." 

 

7.          Section
6.3 of the Agreement shall be amended to read as follows:

 

"6.3           Any
Company shares issued according to this Agreement will be duly and validly issued, fully paid and non-assessable and will be free
and clear of all liens, charges, claims and encumbrances imposed by or through the Company, conferring onto their holder such rights,
preferences and privileges as set forth in the Company's Amended Articles. The Parties acknowledge that the shares issued according
to this Agreement have not been registered under the Securities Act of 1933 (the "1933 Act"), or under any state securities
or "blue sky" laws of any state of the United States, and, unless so registered, may not be offered or sold in the United
States or, directly or indirectly, to U.S. Persons, as that term is defined in Regulation S under the 1933 Act ("Regulation
S"), except in accordance with the provisions of Regulation S, pursuant to an effective registration statement under the 1933
Act, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act."

 

8.          A
new Section 6.12 will be added to the Agreement to read as follows:

 

"6.12         The
Investor represents and warrants that it is not a U.S. Person, and acknowledges that the Investor is not acquiring the shares as
a result of, and will not itself engage in, any "directed selling efforts" (as defined in Regulation S under the 1933
Act) in the United States in respect of any of the shares which would include any activities undertaken for the purpose of, or
that could reasonably be expected to have the effect of, conditioning the market in the United States for the resale of any of
the shares; provided, however, that the Investor may sell or otherwise dispose of any of the shares pursuant to registration of
any of the Shares pursuant to the 1933 Act and any applicable state securities laws or under an exemption from such registration
requirements and as otherwise provided herein."

 

    2 

     

    

 

9.          Section
12.1 of the Agreement shall be amended to read as follows:

 

"12.1         Upon
Closing, pursuant to Article 49.3 of the Amended Articles, and in accordance with the Investor's current shareholding ratio in
the Company, the Board of Directors of the Company shall appoint a director designated by the Investor to the Board of Directors
of the Company to serve until the next annual general meeting of the shareholders of the Company, at which time the directors of
the Company will be elected by the shareholders in accordance with Section 5.2 of the Agreement."

 

10.         Schedule
2 of the Agreement shall be deleted in its entirety.

 

11.         This
Amendment and the Agreement constitute the entire agreement and understanding between the parties with regard to the Investor's
investment in the Company, and supersede any prior written or oral agreements. Any modifications to this Amendment or the Agreement
must be in writing and signed by the authorized representatives of all of the parties.

 

IN WITNESS WHEREOF,
the parties hereto have caused this Amendment to be executed by their duly authorized representatives.

 

Investor 1:

 

	/s/	 
	中关村转化医学科技有限公司	 

Zhongguancun Translational Medicine Science
& Technology Ltd.

 

	Name:	 	 
	Title:	 	 

 

Investor 2:

 

	/s/	 
	重庆两江源创转化医学科技有限公司  	 

Chongqing Liangjiang Yuanchuang Translational
Medicine Science & Technology Co., Ltd.

 

	Name:	 	 
	Title:	 	 

 

Investor 3:

 

	/s/	 
	北京巴斯巴生物医学工程科技发展有限公司	 

Beijing BASIBA Biomedical Engineering
Science & Technology Development Co., Ltd.

 

	Name:	 	 
	Title:	 	 

 

    3 

     

    

 

Investor 4:

 

	/s/	 
	北京济士大泽生物科技中心	 

Beijing Jishi Daze Biological Science
& Technology Center

 

	Name:	 	 
	Title:	 	 

 

The Company:

 

	/s/ Joshua Herchcovici	 

Nano-Textile Ltd.

 

	Name:	Joshua Herchcovici	 
	Title:	Chairman	 

  

    4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}]]